atrial fibrillation: update 2007
TRANSCRIPT
![Page 1: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/1.jpg)
Atrial Fibrillation: Update 2007
David L. Scher, FACP, FACC, FHRSDirector, Cardiac Electrophysiology
Pinnacle Health System and Associated Cardiologists, PCHarrisburg, PA
Clinical Associate Professor of MedicinePennsylvania State College of Medicine
October 13, 2007
![Page 2: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/2.jpg)
Atrial fibrillation accounts for 1/3 of all
patient discharges with arrhythmia as principal diagnosis.
2% VF
Data source: Baily D. J Am Coll Cardiol. 1992;19(3):41A.
34% Atrial
Fibrillation
18% Unspecified
6% PSVT
6% PVCs
4% Atrial Flutter
9% SSS
8% Conduction
Disease3% SCD
10% VT
![Page 3: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/3.jpg)
Classification
• Paroxysmal: recurrent (>2 episodes) that terminate spontaneously within seven days.
• Persistent: AF with duration greater than seven days, or requiring CV (drugs or electrical). Also includes “longstanding persistent AF” (continuous AF lasting greater than one year).
• Permanent: AF in which decision not to restore SR by any means is made.
![Page 4: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/4.jpg)
Atrial Fibrillation: Cardiac Causes• Hypertensive heart disease
• Ischemic heart disease
• Valvular heart disease
– Rheumatic: mitral stenosis
– Non-rheumatic: aortic stenosis, mitral regurgitation
• Pericarditis
• Sinus node dysfunction
• Cardiomyopathy
– Hypertrophic
– Idiopathic dilated (? cause vs. effect)
• Post-coronary bypass surgery
![Page 5: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/5.jpg)
Atrial Fibrillation: Non-Cardiac Causes
• Pulmonary
– COPD
– Pneumonia
– Pulmonary embolism
• Metabolic
– Thyroid disease: hyperthyroidism
– Electrolyte disorder
– Acidemia, sepsis, other hyperadrenergic states
• Toxic: alcohol (‘holiday heart’ syndrome)
![Page 6: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/6.jpg)
AF: Pathophysiology
Wavelets
![Page 7: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/7.jpg)
AF: Pathophysiology
Wyse and Gersch, Circulation, 2004;109:3089-3095
![Page 8: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/8.jpg)
AF: Pathophysiology
Wyse and Gersch, Circulation, 2004;109:3089-3095
![Page 9: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/9.jpg)
Why Treat AF?
Wyse and Gersch, Circulation, 2004;109:3089-3095
![Page 10: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/10.jpg)
2006 ACC/AHA/ESC Practice Guidelines: Changes Since 2001 Guidelines
• Incorporation of major clinical trials.• Reorganized with emphasis on clinical patient
management.• Incorporation of catheter-based ablation technologies.• Drug therapy: those approved in N. America and
Europe• Emerging importance of angiotensin inhibition.• Prophylactic therapies.
JACC 2006, 48:e149-246
![Page 11: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/11.jpg)
Rate Control vs. Rhythm Control
StudiesAFFIRM (2002)
RACE (2002)PAF (2000)
STAF (2003)HOT CAFE’ (2004)
No study demonstrated a difference in quality of life!
![Page 12: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/12.jpg)
Rate Control vs. Rhythm Control
• However, judgment should be exercised in applying this lack of difference of QOL to individual patients!
• Definition of rate control: less than 100 bpm over at least 18 hr monitoring period, or less than 100% of maximum age-adjusted predicted exercise heart rate.
• Regardless of treatment strategy, antithrombotic therapy is to be continued in indicated patients!
![Page 13: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/13.jpg)
Clinical Management
![Page 14: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/14.jpg)
Clinical Management
![Page 15: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/15.jpg)
Clinical Management
![Page 16: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/16.jpg)
Clinical Management: Which AA Drug?
![Page 17: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/17.jpg)
Catheter and Surgical Ablation of AF
![Page 18: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/18.jpg)
Atrial Fibrillation Ablation: HRS/EHRA/ECAS Expert Consensus
Statement
• Electrophysiologic basis and rationale
• Patient Selection
• Methods
• Complications
• Appropriate follow-up and long-term management
![Page 19: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/19.jpg)
Ablation: Electrophysiologic Basis
Traditional Theory: Wavelets
![Page 20: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/20.jpg)
Spontaneous Initiation of Atrial Fibrillation by Ectopic Beats Originating in the Pulmonary Veins
Michel Haïssaguerre, M.D., Pierre Jaïs, M.D., Dipen C. Shah, M.D., Atsushi Takahashi, M.D., Mélèze Hocini, M.D.,
Gilles Quiniou, M.D., Stéphane Garrigue, M.D., Alain Le Mouroux, M.D., Philippe Le Métayer, M.D., and Jacques
Clémenty, M.D
Previous
Next
Volume 339:659-666
September 3, 1998
Number 10
![Page 21: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/21.jpg)
Embryology of the Pulmonary Veins
![Page 22: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/22.jpg)
Pulmonary Veins
![Page 23: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/23.jpg)
Catheter Ablation of AF: Different Approaches
![Page 24: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/24.jpg)
Patient Selection• Symptomatic AF refractory or intolerant to at least
one Class 1 or class 3 antiarrhythmic drug.
• Only absolute contraindication: LA thrombus (TEE before ablation in pts. with persistent AF).
• Other considerations:– Success less likely in pts. with marked LA dilatation.– Higher complication rate in very elderly.– Pts.’ desire to discontinue warfarin is not an
appropriate sole indication for ablation.
![Page 25: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/25.jpg)
Complications
• Cardiac tamponade• Pulmonary vein stenosis• Atrio-esophageal fistula• Phrenic nerve injury• Thromboembolism
![Page 26: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/26.jpg)
Complications
• Air embolism• Post-procedural arrhythmias• Vascular complications• Acute coronary occlusion• Periesophageal vagal injury
![Page 27: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/27.jpg)
Appropriate Follow-up and Long-Term Management: Areas of Consensus
• IV or LMW heparin bridging.
• Warfarin for at least 2 months in all patients.
• Decision re: warfarin after 2 months based on pt. risk factors NOT presence or absence of AF.
• Long-term warfarin for pts. With CHADS > 2.
![Page 28: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/28.jpg)
Appropriate Follow-up and Long-Term Management: Areas of Consensus
• Repeat procedures: to be deferred for at least 3 months, if symptoms can be controlled with drugs.
• Definition of major complication: permanent injury, death, requiring intervention for treatment, or prolong or require hospitalization.
![Page 29: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/29.jpg)
Appropriate Follow-up and Long-Term Management: Areas of Consensus
• Definition of success: freedom from AF/flutter/tachycardia is primary endpoint. Has varied: freedom for AF w/ and w/o sx, 90% reduction of AF burden, presence of AA drugs.
• Recurrence defined as AF/flutter/tachycardias documented lasting > 30 seconds (does not include early recurrence blanking period of 3 months).
• Early recurrence common and not failure: 35%, 40%, 45% at 15, 30, and 60 days respectively.
• Late recurrence (> 1 yr): 5-10%.
![Page 30: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/30.jpg)
Appropriate Follow-up and Long-Term Management: Areas of Consensus
• Minimal monitoring: – office F/U 3 months post ablation and Q 6 mos. for 2
yrs.
– Event recorder monitoring for palpitations.
– 24-hour Holter monitoring at 3-6 mo. intervals for 1-2 yrs for clinical trials.
![Page 31: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/31.jpg)
Literature Review: Non-randomized trials
• Single procedure success, %:– Paroxysmal AF: >60 (38-78)
– Persistent: <30 (22-45)
– Mixed: 16-84
• Multiple procedure success, %:– Paroxysmal: >70, (37-88)
– Persistent: >50 (37-88)
– Mixed: 31-80.
![Page 32: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/32.jpg)
Literature Review: 5 Randomized trials
• 2005:70 pts randomized flecainide/sotalol or ablation:– recurrence= AF w/ or w/o sx.
– AA: 63%
– Abl: 13%
• 2006: (146 pts) Persistent AF CV vs. ablation:– Recurrence: freedom from AF/AFL w/o drugs.
– CV: 58%
– Abl: 74%
![Page 33: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/33.jpg)
Literature Review: 5 Randomized trials
• 2006: (137 pts) Prospective: Role of abl as adjunctive Rx:– Recurrence: AA: 81%, ablation + AA: 45%
• 2006: (199 pts) Randomized, prospective: AA vs ablation:– Recurrence: AA: 78%, ablation: 14%
• 2006: (112 pts) AA vs ablation:– Recurrence: AA: 93%, ablation: 25%
– 63% of AA pts crossed over to ablation
![Page 34: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/34.jpg)
Catheter Ablation of AF
J Cardiovasc Electrophysiol. 2006;17:1-6
![Page 35: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/35.jpg)
![Page 36: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/36.jpg)
![Page 37: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/37.jpg)
Surgical Ablation of AF
• Concomitant to other open heart operations.
• Stand alone surgery for AF.
![Page 38: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/38.jpg)
Surgical Ablation of AF: Concomitant to other open heart operations
• Rationale:
– AF is an independent predictor of late mortality.
– AF associated with higher periop mortality.
– Majority of pts with persistent AF before surgery remain unless treated at time of surgery.
![Page 39: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/39.jpg)
Surgical Ablation of AF: Concomitant to Other Open Heart Operations
• Involves cryoablation, mocrowave, or RF ablation isolation of pulmonary veins and LA lesions (including line to MV-LA isthmus).
– Results: 76%success with LA isthmus lesions, 29% without (mean F/U 41 mos).
– LA appendage occlusion should be strongly considered.
– Results highly variable depending on energy source and completeness of ablation lines.
![Page 40: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/40.jpg)
Stand-alone Surgical Ablation
Surgical Maze Procedure
Cox JL et al. Ann of Surgery 1996;224(3):267-75.
![Page 41: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/41.jpg)
Cox MAZE III Procedure
Cox JL et al. Ann of Surgery 1996;224(3):267-75.
![Page 42: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/42.jpg)
![Page 43: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/43.jpg)
![Page 44: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/44.jpg)
![Page 45: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/45.jpg)
Bipolar clamp ablation
![Page 46: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/46.jpg)
Gross Pathology
Atrial Appendage
![Page 47: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/47.jpg)
Stand-alone Surgical Ablation of AF
![Page 48: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/48.jpg)
Thromboembolic Risk: Pathophysiology
• Wyse and Gersch, Circulation, 2004;109:3089-3095
![Page 49: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/49.jpg)
Thromboembolic Risk Stratification: Who Needs Anticoagulation?
![Page 50: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/50.jpg)
Thromboembolic Risk Stratification: Who Needs Anticoagulation?
![Page 51: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/51.jpg)
Thromboembolic Risk Stratification: Who Needs Anticoagulation?
![Page 52: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/52.jpg)
Thromboembolic Risk Stratification: Who Needs Anticoagulation?
![Page 53: Atrial Fibrillation: Update 2007](https://reader035.vdocuments.site/reader035/viewer/2022081504/556db831d8b42aed2e8b4863/html5/thumbnails/53.jpg)
SUMMARY
• AF is the most common arrhythmia for which pts. are hospitalized.
• AF is associated with an icreased risk of morbidity and mortality.
• Rhythm control is not necessary in older pts. with minimal or absence of symptoms.
• AA drugs should be chosen based on side effect and proarrhythmic potential, not efficacy (except amio).
• Catheter and surgical ablation are effective in symptomatic pts. unresponsive to medical Rx.
• Antithrombotic therapy guidelines should be followed.